LifeStance Q3 revenue up 21% to $262.9M, net loss widens to $61.6M, raises FY guidance midpoints

LifeStance Health Group, Inc.

Revenue $262.9M (+21% YoY); clinicians up 18% to 6,418 with record organic recruiting.
Net loss $61.6M vs $37.9M, driven by class action settlement and stock-based comp.
Adjusted EBITDA $14.6M (5.6% of revenue) vs $15.4M (7.1%) last year.
Raising FY 2023 guidance: revenue $1.03-1.04B, Center Margin $292-300M, Adjusted EBITDA $56-60M.
Q4 2023 outlook: revenue $255-265M, Center Margin $73-81M, Adjusted EBITDA $17-21M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LifeStance Health Group, Inc. reported the third quarter ended September 30, 2023 results: revenue $262.9 million, net income Net loss of $61.6 million. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $262.9 million
Net income: Net loss of $61.6 million
Guidance: raised
Result: reported results

Exact text from the filing

third quarter ended September 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2023 Highlights and FY 2023 Outlook • Total revenue of $262.9 million increased $45.3 million or 21% compared to total revenue of $217.6 million • Total clinicians of 6,418 up 18%, a sequential net increase of 286 in the third quarter • Net loss of

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

LifeStance Health Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.